Kingmed Diagnostics(SH:603882) Xin Lang Cai Jing·2025-09-22 07:18Core Viewpoint - Kingmed Diagnostics has experienced a continuous decline in stock price, with a total drop of 7.11% over the past six days, indicating potential concerns among investors regarding the company's performance and market conditions [1]. Company Overview - Kingmed Diagnostics, established on May 26, 2006, and listed on September 8, 2017, is located in Guangzhou, Guangdong Province. The company provides a wide range of diagnostic services to over 23,000 medical institutions across China, offering nearly 80 types of testing technologies and approximately 3,200 testing projects [1]. - The main revenue composition of Kingmed Diagnostics includes: 91.20% from medical diagnostic services, 6.45% from sales of diagnostics, 1.47% from other services, 0.62% from cold chain logistics, and 0.27% from health check-up services [1]. Shareholder Insights - Among the top shareholders of Kingmed Diagnostics, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 84,000 shares in the second quarter, now holding 9.13 million shares, which accounts for 1.98% of the circulating shares. The estimated floating loss today is approximately 3.74 million yuan, with a total floating loss of 21.18 million yuan during the six-day decline [2]. - The Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 26.15 billion yuan. Year-to-date returns are 18.89%, ranking 2640 out of 4222 in its category, while the one-year return is 42.38%, ranking 2435 out of 3813 [2].